866-997-4948(US-Canada Toll Free)

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 41 Pages

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2016, provides in depth analysis on Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
- The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Overview 6
Therapeutics Development 7
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Stage of Development 7
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Therapy Area 8
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Indication 9
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Products Glance 10
Early Stage Products 10
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Companies 11
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Universities/Institutes 13
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Companies Involved in Therapeutics Development 20
ALSP, Inc. 20
BioMAS Ltd. 21
Oncomatryx Biopharma, S.L. 22
Phelix Therapeutics, LLC 23
Virobay Inc. 24
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Drug Profiles 25
ALP-496 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CIBP-4 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
OMTX-001 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
SAS - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecule to Inhibit Cathepsin B for Oncology - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecules to Inhibit Cathepsin B for Alzheimer's Disease - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
VBY-129 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
VBY-285 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
VBY-376 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
VBY-825 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Dormant Projects 37
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Featured News & Press Releases 38
Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent 38
Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference January 25-27 in Santa Fe, New Mexico 38
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by ALSP, Inc., H2 2016 20
Pipeline by BioMAS Ltd., H2 2016 21
Pipeline by Oncomatryx Biopharma, S.L., H2 2016 22
Pipeline by Phelix Therapeutics, LLC, H2 2016 23
Pipeline by Virobay Inc., H2 2016 24
Dormant Projects, H2 2016 37

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Actions, H2 2016 16
Number of Products by Stage and Routes of Administration, H2 2016 17
Number of Products by Molecule Types, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *